NCT04083807已完成3 期
A Randomised Controlled Multicenter Single-blinded Phase III Study to Evaluate the Efficacy and Safety of TISSEEL Lyo Compared to Manual Compression as an Adjunct to Haemostasis During Vascular Surgery
适应症
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 104
- 试验地点
- 6
- 主要终点
- Number of participants achieving hemostasis at 4 minutes after treatment
研究概览
简要总结
The primary objective of the study is to evaluate the efficacy of TISSEEL Lyo for haemostasis in patients receiving peripheral vascular prosthetic expanded polytetrafluoroethylene (ePTFE) conduits, as compared to a control arm treated with manual compression with surgical gauze pads.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Single (Participant)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Signed informed consent;
- •Male or female ≥ 18 ages;
- •Patients undergoing primary vascular surgery (i.e., conduit placement with an ePTFE graft), including the following:
- •Arterio-arterial-bypass;
- •Ilio-femoral bypass;
- •Femoro-femoral bypass;
- •Ilio-popliteal bypass;
- •Femoro-popliteal bypass;
- •Femoro-tibial vessel bypass
- •Arteriovenous shunting for dialysis access in the upper or lower extremity;
- •Intraoperative inclusion criterion:
- •Suture line bleeding eligible for study treatment is present after surgical hemostasis.
排除标准
- •Concurrent participation in another clinical study treatment with another investigational drug or device within last 30 days;
- •Other vascular procedures during the same surgical session;
- •Arterio-arterial bypasses with more than two anastomoses;
- •Haemoglobin <9.0 g/dL at screening;
- •Pregnant or lactating women;
- •Congenital or acquired coagulation disorders;
- •Prior kidney transplantation;
- •Heparin-induced thrombocytopenia;
- •Known prior exposure to aprotinin within the last 12 months;
- •Known hypersensitivity to aprotinin, heparin, blood products or other components of the investigational product;
- •Unwilling to receive blood products.
- •Known severe congenital or acquired immunodeficiency;
- •Prior radiation therapy to the operating field;
- •Severe local inflammation at the operating field;
- •Positive results of any of the following the blood tests: HIV, syphilis, hepatitis B, hepatitis C.
- •Emergency surgery.
- •Alcohol or drug abuse.
- •Intraoperative exclusion criteria:
- •Major intraoperative complications that required resuscitation or deviation from the planned surgical procedure;
- •Intraoperative change in planned surgical procedure, which resulted in patient no longer meeting preoperative inclusion criteria or having preoperative exclusion criteria.
结局指标
主要结局
Number of participants achieving hemostasis at 4 minutes after treatment
时间窗: Day 0 (4 minutes post-treatment to closure of surgical wound)
Performed on suture line.
次要结局
- Number of participants achieving hemostasis at 6 minutes after treatment(Day 0 (6 minutes post-treatment to closure of surgical wound))
- Number of participants with postoperative re-bleeding after hemostasis(Day 1 (postoperative))
- Number of participants achieving hemostasis at 10 minutes after treatment(Day 0 (10 minutes post-treatment to closure of surgical wound))
- Number of participants with intraoperative re-bleeding after hemostasis(Day 0 (intraoperative))
研究者
研究点 (6)
Loading locations...
相似试验
已完成
3 期
TachoSil Paediatric Liver Trial (TC-019-IN)Liver DiseasesNCT00365248Nycomed16
已完成
1 期
A Phase 1, Single Dose Study of JZP-386 to Evaluate Safety, Pharmacokinetics and PharmacodynamicsNarcolepsy, Excessive Daytime SleepinessNCT02215499Concert Pharmaceuticals28
已完成
不适用
Non-interventional Trial About Treatment of Haemorrhages in Cholecystectomy With TachoSil (TC-027-DE)HemorrhageNCT00546169Nycomed500
已完成
不适用
Evaluate the Safety and Efficacy of Dura Sealant Patch in Reducing CSF Leakage Following Elective Cranial SurgeryCerebrospinal Fluid LeakNCT04086550Polyganics BV228
招募中
2 期
A Study to Evaluate Tislelizumab Combined With Sitravatinib as Adjuvant Therapy in Participants With HCC at High Risk of Recurrence After Curative ResectionHepatocellular CarcinomaNCT05407519Anhui Provincial Hospital40